Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor
	Acts as a drug target

Gene: FOS

Summary for FOS

Gene information	Gene symbol	FOS
	Ensembl ID	ENSG00000170345
	Entrez ID	2353
	Gene name	Fos proto-oncogene, AP-1 transcription factor subunit
	Synonyms	AP-1\|c-fos
	Gene type	protein_coding
	UniProtAcc	P01100

Top

Dataset with differentially expressed gene: FOS

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.85345	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.626943	1.39e-17
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	1.10868	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.695598	3.52e-29
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-1.08892	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	1.26768	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	1.2813	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.770956	6.38e-12
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	-0.682735	4.73e-12
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	1.21851	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.617473	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.635704	5.13e-11
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.650935	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.338518	1.03e-05
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	cDCs	-0.484278	1.34e-09
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.438445	3.54e-06
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.727001	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	1.22715	3.00e-31
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.571178	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.315246	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	NK cells	0.327323	6.48e-03
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	0.259828	2.63e-20
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	-0.348591	4.46e-30
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	0.895546	4.51e-14
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	0.832409	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-2.32057	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-2.93443	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	B cells	-0.289776	2.38e-02
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	CD4+ T cells	-0.284247	1.14e-15
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	Mono/Macro	0.263601	1.26e-43
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	NK cells	0.336638	1.00e-09
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.34027	1.69e-30
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD4+ T cells	0.632729	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.921862	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.581475	1.40e-45
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mast cells	0.841949	1.39e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.768993	2.13e-09
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD8+ T cells	-0.760972	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD4+ T cells	-0.550304	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	Mono/Macro	-0.424082	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.712303	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	-0.356853	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	1.05174	7.44e-43
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.461854	1.50e-15
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.743987	8.83e-12
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.734341	4.98e-20
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.594521	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.762859	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.831329	5.87e-11
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	2.04934	2.16e-41
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	cDCs	2.06523	1.65e-14
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD4+ T cells	1.29808	2.02e-05
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	1.53102	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	0.775393	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	-0.954114	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-1.54402	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-1.72489	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD4+ T cells	-0.997838	1.14e-03
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	0.299254	2.16e-04
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	0.593815	1.16e-11
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Erythrocytes	1.4943	7.60e-08
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.397301	1.41e-07
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-1.09387	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	CD4+ T cells	-0.519438	2.46e-16
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.827224	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.724763	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.302242	1.34e-30
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	0.999614	2.52e-21
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	1.56985	1.42e-39
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	0.601843	7.61e-04
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Mono/Macro	0.93918	3.94e-04
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	-0.530065	7.96e-06
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	0.360696	2.49e-08
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.715534	3.81e-39
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.853229	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	-0.645259	4.00e-28
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.446849	6.02e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	1.2755	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.304787	0.00e+00

Top

Expression of FOS in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to FOS

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating FOS

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
FOS	hsa-miR-589-3p	96.6261	NM_005252
FOS	hsa-miR-490-5p	96.4678	NM_005252
FOS	hsa-miR-569	96.4633	NM_005252
FOS	hsa-miR-155-5p	95.535	NM_005252
FOS	hsa-miR-139-5p	94.9124	NM_005252
FOS	hsa-miR-101-3p	94.1431	NM_005252
FOS	hsa-miR-4650-3p	93.9502	NM_005252
FOS	hsa-miR-3148	93.3446	NM_005252
FOS	hsa-miR-4802-3p	93.0752	NM_005252
FOS	hsa-miR-10527-5p	92.5083	NM_005252
FOS	hsa-miR-335-3p	91.9721	NM_005252
FOS	hsa-miR-4267	91.4618	NM_005252
FOS	hsa-miR-3688-3p	90.6525	NM_005252
FOS	hsa-miR-6124	90.3211	NM_005252
FOS	hsa-miR-10523-5p	90.2848	NM_005252
FOS	hsa-miR-6749-3p	89.2691	NM_005252
FOS	hsa-miR-4772-5p	88.1828	NM_005252
FOS	hsa-miR-627-3p	87.8807	NM_005252
FOS	hsa-miR-6831-5p	87.3143	NM_005252
FOS	hsa-miR-3927-3p	87.3143	NM_005252
FOS	hsa-miR-144-3p	87.0609	NM_005252
FOS	hsa-miR-9500	86.7538	NM_005252
FOS	hsa-miR-338-3p	86.1195	NM_005252
FOS	hsa-miR-4530	85.589	NM_005252
FOS	hsa-miR-3163	85.0972	NM_005252
FOS	hsa-miR-3065-3p	84.812	NM_005252
FOS	hsa-miR-4279	83.7721	NM_005252
FOS	hsa-miR-383-5p	83.0142	NM_005252
FOS	hsa-miR-891a-3p	82.4121	NM_005252
FOS	hsa-miR-5008-5p	81.732	NM_005252
FOS	hsa-miR-548x-3p	81.2764	NM_005252
FOS	hsa-miR-548aj-3p	81.2764	NM_005252
FOS	hsa-miR-548aq-3p	80.8027	NM_005252
FOS	hsa-miR-548ae-3p	80.8027	NM_005252
FOS	hsa-miR-548j-3p	80.8027	NM_005252
FOS	hsa-miR-548ah-3p	80.8027	NM_005252
FOS	hsa-miR-548am-3p	80.8027	NM_005252

Page: 1

Top

Motifs and transcription factors (TFs) regulating FOS

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
FOS	metacluster_9.7	GBX1 (directAnnotation).
FOS	metacluster_9.9	EMX2 (directAnnotation).
FOS	metacluster_9.10	EVX1 (directAnnotation).
FOS	transfac_pro__M12441	ZNF281 (inferredBy_Orthology).
FOS	tfdimers__MD00432	DBP; STAT1 (directAnnotation).
FOS	metacluster_141.2	E2F2; E2F3 (directAnnotation).
FOS	transfac_pro__M02279	CREB1 (directAnnotation).
FOS	metacluster_180.3	ATF2; ATF2; ATF2; ATF2; ATF3; ATF3; ATF4; ATF4; ATF6; ATF6B; ATF7; ATF7; BACH2; BATF3; BATF3; CREB1; CREB1; CREB3; FOSL1; FOSL2; JDP2; JUN; JUN; JUN; JUND; JUND; XBP1; ZBTB21 (directAnnotation). JDP2; JDP2; JUND (inferredBy_Orthology).
FOS	hocomoco__FOXP1_HUMAN.H11MO.0.A	FOXP1 (directAnnotation).
FOS	tfdimers__MD00376	HOXA13; KLF4 (directAnnotation).
FOS	transfac_public__M00039	CREB1 (directAnnotation).
FOS	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
FOS	transfac_pro__M06104	ZNF16 (directAnnotation).
FOS	metacluster_132.4	MEF2B; MEF2B; MEF2B; MEF2B; MEF2C; MEF2C; MEF2D; MEF2D; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF (directAnnotation). SRF; SRF; SRF; SRF (inferredBy_Orthology).
FOS	taipale_tf_pairs__FLI1_DLX2_RSCGGAARYAATTA_CAP	DLX2; FLI1 (directAnnotation).
FOS	metacluster_26.10	SOX21; SOX7; SOX8 (directAnnotation).
FOS	metacluster_155.13	ZNF135 (directAnnotation).
FOS	transfac_pro__M04746	E2F1 (directAnnotation).
FOS	transfac_pro__M08803	CREM (directAnnotation).
FOS	transfac_pro__M05759	ZNF544 (directAnnotation).
FOS	metacluster_2.7	IRF1; IRF1; IRF2; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF7; IRF8; IRF8; IRF9; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; STAT1; STAT1; STAT2 (directAnnotation). PRDM1; PRDM1; PRDM1 (inferredBy_Orthology).
FOS	transfac_pro__M07981	ATF3 (inferredBy_Orthology).
FOS	transfac_pro__M04950	EGR1 (directAnnotation).
FOS	transfac_pro__M05901	ZNF561 (directAnnotation).
FOS	transfac_public__M00041	ATF2; JUN (directAnnotation).
FOS	transfac_pro__M06410	ZNF497 (directAnnotation).
FOS	metacluster_111.5	E4F1; E4F1 (directAnnotation).
FOS	transfac_pro__M05636	ZNF134; ZNF154; ZNF256; ZNF304; ZNF418; ZNF419; ZNF480; ZNF548; ZNF549; ZNF552; ZNF561; ZNF562; ZNF584; ZNF586; ZNF587B; ZNF610; ZNF772; ZNF773; ZNF792; ZNF793; ZNF837 (inferredBy_Orthology).
FOS	transfac_pro__M07323	IRF4 (directAnnotation).
FOS	swissregulon__hs__LEF1	LEF1 (directAnnotation).
FOS	metacluster_82.4	ZFP30 (directAnnotation).
FOS	taipale_tf_pairs__GCM1_HOXB13_RTGCGGGTAATAAAN_CAP	GCM1; HOXB13 (directAnnotation).
FOS	transfac_pro__M06540	ZNF540 (directAnnotation).
FOS	cisbp__M00821	AR (inferredBy_Orthology).
FOS	homer__VCAGGTRDRY_ZEB1	ZEB1 (directAnnotation).
FOS	metacluster_187.8	ZNF22 (directAnnotation).
FOS	transfac_public__M00203	GATA1; GATA2; GATA3 (directAnnotation).
FOS	tfdimers__MD00359	CEBPA; CEBPB; CEBPD; CEBPE; CEBPG; STAT6 (directAnnotation).
FOS	jaspar__MA1108.2	MXI1 (directAnnotation).
FOS	transfac_pro__M06918	ZNF652 (directAnnotation).
FOS	transfac_pro__M06734	ZNF71 (directAnnotation).
FOS	tfdimers__MD00408	ELF1; ELF2; ELF4; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV4; ETV6; ETV7; FLI1; GABPA; GABPB1; GFI1; GFI1B; SPI1; SPIB (directAnnotation).
FOS	cisbp__M04036	FOSL1 (directAnnotation).
FOS	taipale_tf_pairs__POU2F1_ELK1_NCCGGATATGCAN_CAP	ELK1; POU2F1 (directAnnotation).
FOS	transfac_pro__M06301	ZNF404 (directAnnotation).
FOS	transfac_pro__M06482	ZNF547 (directAnnotation).
FOS	cisbp__M05844	ZEB1 (inferredBy_Orthology).
FOS	transfac_pro__M06763	ZNF225 (directAnnotation).
FOS	metacluster_15.4	SMAD6 (directAnnotation). SMAD6 (inferredBy_Orthology).
FOS	metacluster_178.11	POU1F1; POU1F1; POU3F1; POU3F2; POU3F2; POU3F4; POU3F4 (directAnnotation). SATB1; SATB2 (inferredBy_Orthology).

Page: 1 2 3 4 5 6 7

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

TF	motif	Expression	Cell type	Dataset	Timepoint
FOS	metacluster_157.2	down	CD4+ T cells	GSE111014	pre
FOS	jaspar__MA1951.1	down	CD4+ T cells	GSE111014	pre
FOS	metacluster_174.2	down	Malignant cells	GSE131984_Pac	NA
FOS	metacluster_137.2	down	Malignant cells	GSE131984_Pac	NA
FOS	metacluster_174.2	up	Malignant cells	GSE131984_Pal	NA
FOS	tfdimers__MD00090	down	CD4+ T cells	GSE161801_IMiD	post
FOS	metacluster_111.4	down	CD8+ T cells	GSE161801_IMiD	post
FOS	metacluster_137.2	down	CD8+ T cells	GSE161801_IMiD	post
FOS	metacluster_174.2	up	Malignant cells	GSE161801_IMiD	pre
FOS	jaspar__MA1951.1	up	CD4+ T cells	GSE161801_PI	post
FOS	metacluster_111.4	up	CD4+ T cells	GSE161801_PI	post
FOS	metacluster_148.1	up	CD4+ T cells	GSE161801_PI	post
FOS	metacluster_157.2	up	CD4+ T cells	GSE161801_PI	post
FOS	jaspar__MA1951.1	up	CD8+ T cells	GSE161801_PI	post
FOS	metacluster_111.4	up	CD8+ T cells	GSE161801_PI	post
FOS	metacluster_148.1	up	CD8+ T cells	GSE161801_PI	post
FOS	metacluster_111.4	up	cDCs	GSE161801_PI	post
FOS	metacluster_174.2	up	Malignant cells	GSE161801_PI	post
FOS	metacluster_174.2	up	NK cells	GSE161801_PI	post
FOS	metacluster_157.2	up	NK cells	GSE161801_PI	post
FOS	tfdimers__MD00141	up	NK cells	GSE161801_PI	post
FOS	transfac_pro__M02280	up	NK cells	GSE161801_PI	post
FOS	metacluster_50.1	up	NK cells	GSE161801_PI	post
FOS	jaspar__MA1951.1	up	NK cells	GSE161801_PI	post
FOS	jaspar__MA1951.1	down	CD4+ T cells	GSE161801_PI	pre
FOS	tfdimers__MD00475	down	CD4+ T cells	GSE161801_PI	pre
FOS	tfdimers__MD00586	down	Mono/Macro	GSE161801_PI	pre
FOS	tfdimers__MD00141	down	NK cells	GSE161801_PI	pre
FOS	tfdimers__MD00519	down	NK cells	GSE161801_PI	pre
FOS	tfdimers__MD00090	up	CD4+ T cells	GSE162117	post
FOS	metacluster_50.1	up	CD4+ T cells	GSE162117	post
FOS	metacluster_137.2	up	CD4+ T cells	GSE162117	post
FOS	metacluster_157.2	up	cDCs	GSE162117	post
FOS	tfdimers__MD00475	up	Erythrocytes	GSE162117	post
FOS	tfdimers__MD00141	up	Erythrocytes	GSE162117	post
FOS	metacluster_137.2	down	CD4+ T cells	GSE162117	pre
FOS	metacluster_157.2	down	CD4+ T cells	GSE162117	pre
FOS	metacluster_137.5	down	CD4+ T cells	GSE162117	pre
FOS	transfac_pro__M02280	down	CD4+ T cells	GSE162117	pre
FOS	metacluster_174.2	up	Malignant cells	GSE163836	NA
FOS	metacluster_157.2	up	Mono/Macro	GSE169246_PacAteBlood	post
FOS	metacluster_157.2	up	cDCs	GSE169246_PacAteBlood	pre
FOS	metacluster_137.2	up	cDCs	GSE169246_PacAteBlood	pre
FOS	metacluster_157.2	up	CD4+ T cells	GSE169246_PacAteTissue	pre
FOS	metacluster_174.2	up	CD8+ T cells	GSE169246_PacAteTissue	pre
FOS	jaspar__MA1951.1	up	CD8+ T cells	GSE169246_PacAteTissue	pre
FOS	metacluster_157.2	up	CD8+ T cells	GSE169246_PacAteTissue	pre
FOS	tfdimers__MD00165	down	Mono/Macro	GSE169246_PacBlood	post
FOS	metacluster_157.2	down	Mono/Macro	GSE169246_PacBlood	post
FOS	tfdimers__MD00161	down	Mono/Macro	GSE169246_PacBlood	post

Page: 1 2

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
FOS	"Nadroparin"	DB08813	small molecule
FOS	"Nandrolone decanoate"	DB08804	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."